Katherine A. Hoadley

Jul 17, 2024 | biorxiv.org | Ian R Sturgill |Jesse R. Raab |Katherine A. Hoadley

AbstractAberrant expression of the BAP1 tumor suppressor gene is a prominent risk factor for several tumor types and is important in tumor evolution and progression. Here we performed integrated multi-omic analyses using data from The Cancer Genome Atlas (TCGA) for 33 cancer types and over 10,000 individuals to identify alterations leading to BAP1 disruption.

Jun 10, 2024 | nature.com | Katherine A. Hoadley |Hari Ilangovan |Robin Elgart

AbstractNASA has employed high-throughput molecular assays to identify sub-cellular changes impacting human physiology during spaceflight. Machine learning (ML) methods hold the promise to improve our ability to identify important signals within highly dimensional molecular data. However, the inherent limitation of study subject numbers within a spaceflight mission minimizes the utility of ML approaches.

Mar 28, 2024 | jamanetwork.com | Aranzazu Fernández-Martínez |Institut Jules Bordet |Katherine A. Hoadley |David Venet

Key PointsQuestion  What is the quantitative association between pathologic complete response (pCR) and event-free survival (EFS) by intrinsic subtype and other gene expression signatures in patients with ERBB2/HER2-positive early breast cancer (EBC) treated in the neoadjuvant setting?

Nov 21, 2023 | biorxiv.org | Jesse R. Raab |Katherine A. Hoadley |Ian R Sturgill

AbstractBAP1 is a tumor suppressor gene that was originally studied in uveal melanoma (UVM), kidney renal cell clear cell carcinoma (KIRC), and malignant mesothelioma (MESO). Early analyses focused on single-nucleotide variants, but other alteration types such as larger indels and gene-level copy number (CN) loss can also lead to loss of BAP1 expression. We performed integrated multi-omic analyses using data from The Cancer Genome Atlas (TCGA) for 33 cancer types and more than 10,000 individuals.

Nov 10, 2023 | nature.com | Katherine A. Hoadley |Benjamin Calhoun |J. S. Marron

AbstractApproaches for rapidly identifying patients at high risk of early breast cancer recurrence are needed. Image-based methods for prescreening hematoxylin and eosin (H&E) stained tumor slides could offer temporal and financial efficiency.